BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
Milestone triggers $10 million payment from Eli Lilly and Company
BioMS Medical Corp. announced that the independent Drug Safety Monitoring Board (DSMB) for the MAESTRO-01 trial has conducted the scheduled interim analysis of efficacy and safety and has recommended that the trial continue to completion. MAESTRO-01 is the pivotal phase II/III Canadian and European study of dirucotide (MBP8298) in patients with secondary progressive MS.
The interim analysis included patients from the first 200 to complete MAESTRO-01 and assessed the likelihood of the study reaching its primary endpoint at the end of the trial in MS patients with the target HLA-DR2 and/or HLA-DR4 immune response genes. The DSMB analysis also included a scheduled review of safety information.
Based on the DSMB decision, Eli Lilly and Company has agreed to provide the $10 million milestone payment to BioMS as part of the terms of the licensing and collaboration agreement.
Dirucotide (MBP8298) is a synthetic peptide that consists of 17 amino acids having a sequence identical to that of a portion of human myelin basic protein (MBP). Dirucotide is being developed for the potential treatment of multiple sclerosis (MS), an autoimmune disease caused by immune attack against normal components of the central nervous system. The sequence of dirucotide is associated with the autoimmune process in MS patients with certain immune response genes (HLA types DR2 and/or DR4); MS patients having these genes represent 65 to 75 percent of all MS patients.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Coffee could offer protection from catching COVID-19 - A chemical compound in coffee inhibits the interaction between the corona virus spike protein and the human cell ACE-2 receptor
Crucell and US Navy Sign Agreement to Test AdVac®-based Vaccine Against Anthrax and Plague

Protein team produces molecular barrels - Researchers show that two protein machineries collaborate on the development of barrel structures in the mitochondria
Deinove signs a collaboration agreement with the Tereos group
ImmunoGen, Inc. Expands Pipeline of Targeted Anticancer Compounds - Company to Develop TAP Compound to Novel Target Using Centocor Antibody
Akzo Nobel's new business Nobilon has started operating - Nobilon will develop, produce and market human vaccines -- Diosynth, Intervet and Oregon are expected to give support

Fantastic muscle proteins and where to find them - “This is going to be unexpected even for myosin researchers”
Rigontec GmbH Appoints Dr. Christian Schetter as CEO
Light in sight - Restoring vision to blind mice
Category:Medicinal_chemistry
